CD19 CAR T-Cell detection reagent

PE Human protein CD19



INTENDED USE

Identification and quantification of CDI9 CAR T-Cells by flow cytometry.

2. DESCRIPTION

Source: human CDI9 protein (20-291). Fc Tag. expressed from human 293 cells (HEK) and subsequently fluorochrome-conjugated with a proprietary technology (BrightStep). MW: 56.6

Purification: affinity chromatography.

Composition: human CD19 protein conjugated in an aqueous solution containing a stabilizing protein and 0.09% sodium azide (NaN3).

Recommended Usage: the recommended usage of this reagent is 5 ul for sample volumes ranging from 100 µl (FACS protocol). We recommended reagent tittering for others protocols such as bulk lysis protocol.

Fc (Pro 100 - Lys 330) CD19 (Pro 20 - Lys 291) Protein Accession: P15301_ PO1857

3. APPLICATION FIELD

Flow cytometry reagents play a crucial role in monitoring and evaluating the efficacy of CAR T-Cell therapies (chimeric antigen receptor T-cell therapies). These therapies represent a revolutionary approach in cancer treatment, where a patient's T cells are genetically modified to specifically recognize and attack cancer cells. However, to ensure the success of these therapies, closely monitoring the persistence and activity of CAR T-Cells in the patient's body is crucial.

The reagents used in flow cytometry are essential in this process. Their ability to provide precise identification and quantification of CAR T-Cells in blood or other tissues samples, as well as assessing their viability and function. This is critical to determine whether CAR T-Cells persist in the patient's body at sufficient levels to effectively combat cancer and whether they maintain their ability to recognize and destroy cancer cells.

Immunostep's CDI9 CAR T-Cell is an antigen-based reagent consisting of the human CDI9 extracellular domain (20-291) conjugated to fluorochrome using a proprietary technology (BrightStep™) that enhances the detection of CAR T-Cells.

PRINCIPLE OF METHODOLOGY

Immunostep's CDI9 CAR T reagent has been developed for the detection of transduced T-cells that are engineered to express CDI9-specific chimeric antigen receptor (CAR) on the cell surface by direct immunofluorescence flow cytometry protocol.

STORAGE AND HANDLING CONDITIONS

Store refrigerated between +2 and +8°C. DO NOT FREEZE.

The unopened kit is stable until the expiry date indicated on the vial. Do not use after this date. After opening, reagents are stable if stored at +2 to +8°C and protected light and from contamination.

MATERIALS, REAGENTS AND EQUIPMENT REQUIRED NOT SUPPLIED.

- Buffered saline (PBS) with 0.09% sodium azide. It is recommendable
- Lysing solution. (Ref# RBCIOX-50M), IOX concentrated solution containing ammonium chloride (NH, CI). For use dilute the concentrated RBC Lysis Solution (1:10) (5mL de RBC Lysis Solution 10X +45mL distilled water).
- Antibody panel for CAR T-Cell identification:

PRODUCT DESCRIPTION	REF
OC5I5 Anti-human CD45	450C2-100T 3FI-100T
PerCP-Cy5.5 Anti-human CD4	4PP-100T
APC Anti-human CD8 PE-Cyanine7 Anti-human CD45RA	8AI-IOOT 45RAPC7-IOOT

Table 1: Antibodies which can be used for assessment of CAR T-Cells in the peripheral blood (optional recomendation).

7. RECOMMENDATIONS AND WARNINGS

Co-staining with anti-human CD19 antibodies should be avoided as the CD19 CAR T-Cell detection reagent can also be recognized by CDI9 antibodies.

Before acquiring samples, it is necessary to ensure that the flow cytometer settings and their compensation are appropriate.

The reagents contain sodium azide. In acid conditions, it is transformed into hydrazoic acid, a highly toxic compound. Azide compounds should be dissolved with tap water before disposal. These conditions are recommended to avoid deposits in pipes. Material Safety Data Sheet (MSDS) available on the website www.immunostep.com.

Keep kit components away from direct light exposure during the protocol. Fluorescently conjugated reagents are sensitive to light.

Mear personal protective equipment for sample handling. Wash hands properly after handling specimens. All procedures should be carried out in accordance with approved safety standards.

SAMPLE COLLECTION

The extraction of blood samples should be carried out in blood collection tubes using the appropriate anticoaquiant (EDTA or heparin). For optimum results, the sample should be processed during the six hours following the extraction. It is recommended that samples that cannot be processed withim 48 hours of extraction be discarded.

9. **PROTOCOL**

9.1 **FACS Lysis Protocol**

Protocol for immunofluorescent staining. The protocol can be carried out in a cytometer tube (12x75 mm) (ANNEX I):

- Prepare a staining cocktail containing the volume indicated on the CD19 CAR T-Cell reagent (CD19p) vial and additional conjugated antibodies. See examples in Table 1. For more details, please refer to the respective data sheets.
- Add 100 µL of sample (up to 106 cells) and mix properly in the vortex.
- Incubate in the dark for 30 minutes at room temperature (20-25°C) or for 60 min. at 4°C.
- Add 2 ml of the lysing solution, mix in the vortex and incubate in the dark for 10 15
- Centrifuge at 540g for 5 minutes and carefully withdraw the supernatant by suction so as not to touch the cell pellet. Leave 50 µl of unaspirated liquid to facilitate pellet resuspension.
- Add 2 ml of PBS (please see materials required but not provided).
- Centrifuge at 540g for 5 minutes and carefully withdraw the supernatant by suction so as not to touch the cell pellet. Leave 50 µl of non-aspirated liquid.
- Resuspend the pellet in 0.3 ml of PBS.
- Acquire on a flow cytometer or store in the dark at 2°C -8°C until the analysis is carried out. Samples should be acquired within I hour after lysis.



CART-Cells


CD19p:PE-A

10. CYTOMETER ASSAY ACQUISITION AND ANALYSIS STRATEGY

It is essential in multicolor flow cytometry to correct fluorescence spillover. Each laboratory must establish their own procedures for verifying that compensation is appropriate for your antibody

10.1 Strategy for analysis of samples

A first step of screening the nucleated cell population in the FSC-H/FSC-A pattern to remove residual debris and reduce background is recommended, followed by gating the nucleated cell population in the SSC-A/FSC-A dot plot to remove doublets, allowing correct identification of the lymphocyte population (A). On a dot plot for the following CD45/CD3 gating (B), for selection of the T-lymphocyte population. Finally, in a dot plot for the CAR T-Cell marker (CDI9 CAR T-Cell reagent), for the gating of CAR T-Cells. In this dot plot CD45RA is only used to further define the gating of the CAR T-Cell population.



CD19p:PE-A Figure 1: Analysis strategy for CAR T-Cell population selection in the FSC-H/FSC-A (A); SSC or CD45/CD3 (B) and pCD19 (C) dot plots.

11. WARRANTY

CD19p:PE-A

Warranted only to conform to the quantity and contents stated on the label or in the product labelling at the time of delivery to the customer, Immunostep disclaims hereby other warranties.

Immunostep's sole liability is limited to either the replacement of the products or refund of the purchase price.

Revision nr. 5 (English) | Emission date: 03/2024

12. ADDITIONAL INFORMATION


For research use only. Not for diagnostic use.

Not for resale. Immunostep will not be responsible of violations that may occur with the use of this product. Any use of this product other than the specified in this document is strictly prohibited.

Unless otherwise indicated by Immunostep by written authorization, this product is intended for research only and is not to be used for any other purpose, including without limitation, for human or animal diagnostic, the

Please, refer to www.immunostep.com technical support for more information.

13. EXPLANATION OF SYMBOLS



14. MANUFACTURER'S DATA

IMMUNOSTEP S.L.


Address: Avda. Universidad de Coimbra, s/n
Cancer Research Center (C.I.C)
Campus de Unamuno

37007 Salamanca (Spain) Telf./fax: (+34) 923 294 827

E-mail: info@immunostep.com www.immunostep.com ANNEX I.

Protocol for immunofluorescent staining





Revision nr. 5 (English) | Emission date: 03/2024